Youngen, based in Beijing, is a leading oligonucleotide therapeutic company built around AOC modality. Youngen has been dedicated to develop RNAi therapeutics to a broad spectrum of difficult-to-treat diseases, both rare and general, impacting millions of people and families around the world. Leveraging cutting-edge technological platforms, we build globally competitive diversified product pipelines with first-in-classband Best-in-class potentials.We are advancing programs across key therapeutic areas, including cardiovascular, renal, central nervous system (CNS), and metabolic diseases, to deliver novel treatment options for patients in need.
Youngen is a subsidiary of Beijing Hotgen Biotech Co., Ltd. (SSE:688068). Holding a strong presence in in-vitro diagnostics market, Hotgen is also dedicated to the biopharmaceutical industry, continuously empowering Youngen as a biotech pharmaceutical company in this direction.
As an innovative biotechnology company focused on rna interference therapeutics, Youngen has formed three major technology platforms in extrahepatic targeted delivery, chemical modification, and target selection, with established intellectual property protections.
As a research-driven biotech company, Youngen has an excellent Chief Scientist and a team with rich experience in nucleic acid chemistry, drug discovery, and pharmacology.
As a biopharmaceutical company, Youngen has strong independent clinical development capabilities, with an experienced global clinical development and medical affairs team.
